Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntingtons disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.La présente invention concerne certains composés, ou des sels pharmaceutiquement acceptables ou des promédicaments de ceux-ci. Linvention concerne également des compositions pharmaceutiques comprenant au moins un composé ou un sel ou un promédicament pharmaceutiquement acceptable de celui-ci et un ou plusieurs véhicules pharmaceutiquement acceptables. Linvention concerne des méthodes de traitement de patients souffrant de certaines maladies et de certains troubles qui réagissent à linhibition de lactivité KMO, lesdites méthodes comprenant ladministration, à de tels patients, dune quantité dau moins un composé ou dun sel ou dun promédicament pharmaceutiquement acceptable de celui-ci, qui selon linvention, est efficace pour réduire des signes ou faire régresser des symptômes de la maladie ou du tro
